Panbela Announces Positive Preclinical Data Strongly Supporting the Activity of SBP-101 in Ovarian Cancer Cell Lines; Development Program for SBP-101’s Expansion into Ovarian Cancer Expected in 1H 2022
December 14, 2021 09:00 ET
|
Panbela Therapeutics, Inc.
MINNEAPOLIS, Dec. 14, 2021 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with cancer, today...
Panbela Announces Acceptance of Abstract for Poster Presentation at American Society of Clinical Oncology Gastrointestinal Cancers Symposium
November 18, 2021 09:00 ET
|
Panbela Therapeutics, Inc.
MINNEAPOLIS, Nov. 18, 2021 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients...
Panbela Provides Business Update and Reports Q3 2021 Financial Results
November 10, 2021 16:15 ET
|
Panbela Therapeutics, Inc.
MINNEAPOLIS, Nov. 10, 2021 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients...
Panbela Schedules Conference Call on November 10, 2021, to Report 2021 Third Quarter Financial Results
October 25, 2021 09:00 ET
|
Panbela Therapeutics, Inc.
MINNEAPOLIS , Oct. 25, 2021 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of...
Panbela to Present at Upcoming Investor Conferences
September 07, 2021 09:00 ET
|
Panbela Therapeutics, Inc.
MINNEAPOLIS, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of...
Panbela Provides Business Update and Reports Q2 2021 Financial Results
August 11, 2021 16:12 ET
|
Panbela Therapeutics, Inc.
MINNEAPOLIS, Aug. 11, 2021 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients...
Panbela Announces Issuance of key U.S. Patent; Patent is for Claims of a Novel Process for the Production of SBP-101
August 09, 2021 08:00 ET
|
Panbela Therapeutics, Inc.
MINNEAPOLIS, Aug. 09, 2021 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients...
Panbela Schedules Conference Call on August 11, 2021, to Report 2021 Second Quarter Financial Results
July 28, 2021 09:00 ET
|
Panbela Therapeutics, Inc.
MINNEAPOLIS, July 28, 2021 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of...
Panbela to Present at Access to Giving Virtual Conference on July 15, 2021, at 10:30 a.m. ET
July 07, 2021 08:45 ET
|
Panbela Therapeutics, Inc.
MINNEAPOLIS, July 07, 2021 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients...
PANBELA THERAPEUTICS ANNOUNCES CLOSING OF $10.0 MILLION BOUGHT DEAL OFFERING OF COMMON STOCK
July 02, 2021 16:05 ET
|
Panbela Therapeutics, Inc.
MINNEAPOLIS, July 02, 2021 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA) (the “Company” or “Panbela”), a clinical stage biopharmaceutical company developing disruptive therapeutics...